179 related articles for article (PubMed ID: 23246869)
1. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma.
Chen YL; Jeng YM; Hsu HC; Lai HS; Lee PH; Lai PL; Yuan RH
Int J Surg; 2013; 11(1):85-91. PubMed ID: 23246869
[TBL] [Abstract][Full Text] [Related]
2. IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma.
Gao Y; Yang M; Jiang Z; Woda BA; Mercurio AM; Qin J; Huang X; Zhang F
Hum Pathol; 2014 Jun; 45(6):1184-91. PubMed ID: 24745619
[TBL] [Abstract][Full Text] [Related]
3. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.
Jeng YM; Chang CC; Hu FC; Chou HY; Kao HL; Wang TH; Hsu HC
Hepatology; 2008 Oct; 48(4):1118-27. PubMed ID: 18802962
[TBL] [Abstract][Full Text] [Related]
4. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.
Yuan RH; Wang CC; Chou CC; Chang KJ; Lee PH; Jeng YM
Ann Surg Oncol; 2009 Jun; 16(6):1711-9. PubMed ID: 19357927
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors.
Sasaki M; Sato Y
Hum Pathol; 2017 Apr; 62():152-159. PubMed ID: 28089541
[TBL] [Abstract][Full Text] [Related]
6. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
Sasaki M; Sato Y
Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
9. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas.
Riener MO; Fritzsche FR; Clavien PA; Pestalozzi BC; Probst-Hensch N; Jochum W; Kristiansen G
Hum Pathol; 2009 Oct; 40(10):1377-83. PubMed ID: 19467694
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater.
Kim HG; Park MS; Sung JY; Kim YW; Kim HS; Na K
Anticancer Res; 2019 Sep; 39(9):4947-4955. PubMed ID: 31519600
[TBL] [Abstract][Full Text] [Related]
11. Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma.
Zhang H; Jenkins SM; Lee CT; Harrington SM; Liu Z; Dong H; Zhang L
Hum Pathol; 2018 Aug; 78():97-105. PubMed ID: 29698699
[TBL] [Abstract][Full Text] [Related]
12. Elevation of serum γ-glutamyltransferase as a predictor of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: analysis of a large monocenter study.
Yin X; Zheng SS; Zhang BH; Zhou Y; Chen XH; Ren ZG; Qiu SJ; Fan J
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1408-14. PubMed ID: 23839159
[TBL] [Abstract][Full Text] [Related]
13. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
Chromecki TF; Cha EK; Pummer K; Scherr DS; Tewari AK; Sun M; Fajkovic H; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
BJU Int; 2012 Jul; 110(1):63-8. PubMed ID: 22077633
[TBL] [Abstract][Full Text] [Related]
15. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
[TBL] [Abstract][Full Text] [Related]
17. Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy.
Abe T; Amano H; Shimamoto F; Hattori M; Kuroda S; Kobayashi T; Tashiro H; Ohdan H
Eur J Surg Oncol; 2015 Nov; 41(11):1515-21. PubMed ID: 26210654
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma.
Ohta S; Morine Y; Imura S; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Wada Y; Yamashita S; Bando Y; Shimada M
Anticancer Res; 2019 Nov; 39(11):6025-6033. PubMed ID: 31704828
[TBL] [Abstract][Full Text] [Related]
19. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma.
Dong LW; Hou YJ; Tan YX; Tang L; Pan YF; Wang M; Wang HY
Autophagy; 2011 Oct; 7(10):1222-9. PubMed ID: 21654208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
